Lucia Agarwal
Epigenetic changes have frequently been suggested for the diagnosis and creation of anti-cancer therapy techniques in the search for novel trustworthy biomarkers [1]. In fact, promoter methylation has to be paired with a highly informative technology that is tested in a suitable biospecimens for it to actively become a tumour marker for therapeutic application [2]. In fact, one of the most difficult issues in epigenetic research is methodological uniformity [3]. Additionally, liquid biopsy is being used to supplement and, in some situations, replace tissue-based biopsy [4]. This study will emphasise the improvements made for the prospective use of methylation biomarkers in clinical settings, with a focus on liquid biopsy, for both pre-analytical and analytical application [5]. With the assistance of active interaction with the milieu that makes up the tumour niche, the carcinogenic process progresses through the continuous accumulation of genetic and epigenetic changes that allow it to elude physiological regulation systems [5].
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi